β3-Agonist therapy: A new advance in the management of overactive bladder?

European Urology

Volumn 62, Issue 5, 2012, Pages 841-842

  Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MIRABEGRON; PLACEBO; TOLTERODINE;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HUMAN; MICTURITION; OVERACTIVE BLADDER; PRIORITY JOURNAL; TREATMENT DURATION; URINARY FREQUENCY;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANILINE COMPOUNDS; BENZOATES; BIPHENYL COMPOUNDS; FEMALE; HUMANS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84867074884     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.006     Document Type: Editorial

References (10)

1. E.H. Ohlstein, A. von Keitz, and M.C. Michel A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder Eur Urol 62 2012 834 840
2. C.R. Chapple, O. Yamaguchi, and A. Ridder Clinical proof of concept study (Blossom) shows novel beta 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder [abstract 674] Eur Urol Suppl 7 2008 239
3. C. Chapple, J.J. Wyndaele, P. van Kerrebroeck, P. Radziszewski, V. Dvorak, and P. Boerrigter Dose-ranging study of once-daily mirabegron (YM178), a novel selective β3 adrenoceptor agonist, in patients with overactive bladder (OAB) Eur Urol Suppl 9 2010 249
4. Nitti V, Herschorn S, Auerbach S, et al. The efficacy and safety of mirabegron in patients with overactive bladder syndrome - results from a North-American phase III trial. Presented at: 26th Annual Congress of the European Association of Urology.; March 18-22, 2011; Vienna, Austria.
5. Khullar V, Cambronero J, Ströberg P, et al. The efficacy and tolerability of mirabegron in patients with overactive bladder - results from a European-Australian phase III trial. Presented at: 26th Annual Congress of the European Association of Urology.; March 18-22, 2011; Vienna, Austria.
6. K.E. Andersson, and A. Arner Urinary bladder contraction and relaxation: physiology and pathophysiology Physiol Rev 84 2004 935 986
7. M.C. Michel, and W. Vrydag Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate Br J Pharmacol 147 Suppl 2 2006 S88 S119
8. A. Otsuka, H. Shinbo, and R. Matsumoto Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium Naunyn Schmiedebergs Arch Pharmacol 377 2008 473 481
9. M. Nomiya, and O. Yamaguchi A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders J Urol 170 2003 649 653
10. Y. Igawa, Y. Yamazaki, and H. Takeda Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders J Urol 165 2001 240 244